Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1988-6-8
pubmed:abstractText
The effects of NB-818, isopropyl methyl 2-carbamoyloxy-methyl-6-methyl-4-(2,3-dichlorophenyl)-1,4-dihyd rop yridine-3,5-dicarboxylate, on the cardiovascular system were investigated in comparison with those of nicardipine and nimodipine, using anesthetized dogs. 1) NB-818 1-20 micrograms/kg intravenously (i.v.), nicardipine 0.3-10 micrograms/kg i.v. and nimodipine 0.3-10 micrograms/kg i.v. decreased mean arterial blood pressure (MBP), total peripheral resistance (TPR) and renal blood flow (RBF) and increased cardiac output (CO) and stroke volume (SV), but did not affect heart rate (HR) and PQ-interval. 2) NB-818 1-20 micrograms/kg i.v. increased vertebral blood flow (VBF) dose-dependently, with a moderate decrease of MBP and little or no change in HR or femoral blood flow (FBF). Both nicardipine 0.3-10 micrograms/kg i.v. and nimodipine 0.3-10 micrograms/kg i.v. not only increased VBF in a dose-dependent manner, but also markedly decreased MBP and tended to increase FBF. The increase in VBF with NB-818 was a little less than that with nicardipine and nimodipine, but its effect was significantly slower in onset and of longer duration as compared to nicardipine and nimodipine. 3) The ratio of decrease of vertebral vascular resistance (VR) to decrease of TPR was significantly larger with NB-818 and nimodipine than with nicardipine. 4) NB-818, nicardipine and nimodipine in a range of 0.3-10 micrograms intraarterially (i.a.) increased VBF, and the effect of NB-818 was longer lasting than that of nicardipine and nimodipine. 5) NB-818 0.003-0.1 mg/kg intraduodenally (i.d.) also caused a longer lasting increase in VBF with a slower onset that was accompanied by moderate hypotension and was dose-dependent. The duration of action was significantly longer than that of nimodipine 0.1-0.3 mg/kg i.d. Thus, NB-818 predominantly increases VBF with concomitant moderate hypotension, and its action is of significantly slower onset and longer duration than that of nicardipine and nimodipine.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0301-4533
pubmed:author
pubmed:issnType
Print
pubmed:volume
291
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7-20
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Hemodynamic effects of a dihydropyridine calcium antagonist, NB-818 (NPK-1886) in anesthetized dogs.
pubmed:affiliation
Central Research Laboratories, Banyu Pharmaceutical Co. Ltd., Tokyo, Japan.
pubmed:publicationType
Journal Article